Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality -6% Improvement Relative Risk Hospitalization time -100% Ohl et al. Remdesivir for COVID-19 LATE TREATMENT Is late treatment with remdesivir beneficial for COVID-19? PSM retrospective 2,344 patients in the USA Longer hospitalization with remdesivir (p=0.001) Ohl et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.14741 Favors remdesivir Favors control
Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19
Ohl et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.14741
Ohl et al., Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized.., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.14741
Jul 2021   Source   PDF  
  All Studies   Meta
Retrospective 5,898 hospitalized patients in the USA, 2,374 receiving remdesivir treatment, showing no significant difference in mortality, and a longer time to hospital discharge with treatment.
[Gérard, Wu, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
risk of death, 6.0% higher, HR 1.06, p = 0.66, treatment 143 of 1,172 (12.2%), control 124 of 1,172 (10.6%), adjusted per study, PSM, Cox proportional hazards regression.
hospitalization time, 100% higher, relative time 2.00, p < 0.001, treatment 1,172, control 1,172, PSM, Cox proportional hazards regression.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ohl et al., 15 Jul 2021, retrospective, propensity score matching, USA, peer-reviewed, 9 authors.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperRemdesivirAll
Abstract: Original Investigation | Infectious Diseases Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19 Michael E. Ohl, MD, MSPH; Donald R. Miller, ScD; Brian C. Lund, PharmD; Takaaki Kobayashi, MD; Kelly Richardson Miell, PhD; Brice F. Beck, MA; Bruce Alexander, PharmD; Kristina Crothers, MD; Mary S. Vaughan Sarrazin, PhD Abstract Key Points IMPORTANCE Randomized clinical trials have yielded conflicting results about the effects of remdesivir therapy on survival and length of hospital stay among people with COVID-19. Question Is remdesivir treatment associated with improved survival or shortened hospitalizations among OBJECTIVE To examine associations between remdesivir treatment and survival and length of hospital stay among people hospitalized with COVID-19 in routine care settings. people with COVID-19 in routine care settings? Findings In this cohort study of 2344 DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study used data from the US veterans hospitalized with COVID-19, Veterans Health Administration (VHA) to identify adult patients in 123 VHA hospitals who had a first remdesivir therapy was not associated hospitalization with laboratory-confirmed COVID-19 from May 1 to October 8, 2020. Propensity with improved 30-day survival but was score matching of patients initiating remdesivir treatment to control patients who had not initiated associated with a significant increase in remdesivir treatment by the same hospital day was used to create the analytic cohort. median time to hospital discharge. Meaning The findings suggest that EXPOSURES Remdesivir treatment. routine use of remdesivir may be associated with increased use of MAIN OUTCOMES AND MEASURES Time to death within 30 days of remdesivir treatment initiation (or corresponding hospital day for matched control individuals) and time to hospital hospital beds but not with improvements in survival. discharge with time to death as a competing event. Associations between remdesivir treatment and these outcomes were assessed using Cox proportional hazards regression in the matched cohort. RESULTS The initial cohort included 5898 patients admitted to 123 hospitals, 2374 (40.3%) of whom received remdesivir treatment (2238 men [94.3%]; mean [SD] age, 67.8 [12.8] years) and 3524 (59.7%) of whom never received remdesivir treatment (3302 men [93.7%]; mean [SD] age, + Invited Commentary + Supplemental content Author affiliations and article information are listed at the end of this article. 67.0 [14.4] years). After propensity score matching, the analysis included 1172 remdesivir recipients and 1172 controls, for a final matched cohort of 2344 individuals. Remdesivir recipients and matched controls were similar with regard to age (mean [SD], 66.6 [14.2] years vs 67.5 [14.1] years), sex (1101 men [93.9%] vs 1101 men [93.9%]), dexamethasone use (559 [47.7%] vs 559 [47.7%]), admission to the intensive care unit (242 [20.7%] vs 234 [19.1%]), and mechanical ventilation use (69 [5.9%] vs 45 [3.8%]). Standardized differences were less than 10% for all measures. Remdesivir treatment was not associated with 30-day mortality (143 remdesivir recipients [12.2%] vs 124 controls [10.6%]; log rank P = .26; adjusted hazard ratio [HR], 1.06; 95% CI, 0.83-1.36). Results were similar for people receiving vs not receiving dexamethasone at remdesivir initiation (dexamethasone recipients: adjusted HR, 0.93; 95%..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop